KYT Dental Services
Denosumab · Jaw bone

Denosumab and medication-related osteonecrosis of the jaw (MRONJ)

Quick answer

Denosumab (Prolia, Xgeva) carries an MRONJ risk similar to bisphosphonates, but managed differently because the drug effect reverses within months of stopping. The osteoporosis dose (Prolia, 60 mg every 6 months) has lower MRONJ rates than the cancer dose (Xgeva, given more frequently). Invasive dental work is often timed in the months before the next scheduled injection, when bone turnover has partially recovered. The right move is not to avoid dental care; it is to coordinate it.

The mechanism
How denosumab MRONJ differs from bisphosphonate MRONJ

Denosumab is a monoclonal antibody that blocks RANK ligand, the signal that activates the osteoclasts which break down bone. Without that signal, bone breakdown slows dramatically, which is what makes denosumab effective for osteoporosis and bone protection during cancer treatment. The downside is that the same suppression of bone turnover slows healing at sites of surgical trauma to the jaw, raising MRONJ risk.

The big difference from bisphosphonates is the duration of effect. Bisphosphonates bind tightly to bone and continue working for years after stopping. Denosumab effects fade within months of the last injection. This makes timing of invasive dental procedures more flexible: in patients on the osteoporosis dose (Prolia every 6 months), there is a recognizable window of partial recovery in the weeks before the next dose where dental surgery is generally safer.

The cancer dose (Xgeva, typically every 4 weeks for bone metastases or multiple myeloma) is given more frequently and at higher cumulative doses than Prolia. MRONJ rates with Xgeva are substantially higher than with Prolia. Patients on Xgeva need much more careful coordination between their oncology team and their dentist before any invasive dental work.

Practical steps
What to do if you are on denosumab and need dental work
  • Tell your dentist at scheduling that you are on denosumab and which form (Prolia for osteoporosis or Xgeva for cancer).
  • Tell us when your last injection was and when the next is scheduled. The timing changes how we plan.
  • Address any infected or hopeless teeth promptly. A tooth abscess is harder on the jaw than a planned extraction.
  • Do not skip or delay denosumab on your own. The decision is made with your prescribing physician, and timing dental work around the dose schedule is usually a better approach than stopping the medication.
  • If you are about to start denosumab, have any planned dental work done first if possible. Pre-treatment optimization is one of the highest-leverage protections.
  • Maintain meticulous oral hygiene. The local bacterial load matters for MRONJ risk.
Red flags
When to call your dentist
  • An exposed area of bone in the mouth, even if it is not painful.
  • A tooth socket that is not healing weeks after an extraction.
  • Persistent jaw pain in the area of a recent procedure.
  • A non-healing sore on the gums that has been there more than two weeks.
  • Numbness or tingling in the jaw, lip, or chin (this can be a sign of bone involvement).
Common questions
What patients ask about Denosumab (Prolia) and jaw bone problems (mronj).
Is denosumab MRONJ risk the same as Fosamax?
Similar in magnitude for the osteoporosis dose (Prolia vs oral bisphosphonates), but managed differently because denosumab effects reverse within months of stopping. The cancer dose (Xgeva) carries substantially higher MRONJ risk than oral bisphosphonates.
Should I skip a Prolia dose before a tooth extraction?
Sometimes, but never on your own. Some prescribing physicians plan invasive dental work to occur near the end of a Prolia dose cycle, when bone turnover has partially recovered. Others continue the dose schedule and rely on careful surgical technique. The decision balances multiple factors.
What is the actual MRONJ risk on Prolia?
Estimates put the risk at well under 1 percent in osteoporosis patients on standard Prolia dosing, similar to oral bisphosphonates. The risk rises with treatment duration and is concentrated in patients undergoing invasive dental procedures. Specific risk depends on your full medical history.
Can I get a dental implant on denosumab?
Often yes for Prolia, with appropriate planning and timing. For Xgeva, implants are more cautious territory because the MRONJ risk is higher. The conversation involves your dentist, your prescribing physician, and sometimes an oral surgeon depending on the planned site.
What happens if MRONJ develops around dental work?
Early MRONJ is usually managed conservatively with antibiotics, gentle hygiene, and topical care. Many cases respond. More advanced cases require surgical management with an oral surgeon. The earlier it is caught, the easier it is to treat, which is why close follow-up matters in denosumab patients.
Talk to a dentist about your case
Bring your medication list to your visit.

General guidance is a starting point. Your specific dental plan depends on your medical history, your other medications, and what your mouth looks like in person. Schedule a consultation and we’ll walk through it.

Schedule a consultationCall (833) 598-3368

Reviewed by Dr. Isaac Sun, DDS.

This page is general information, not medical advice. Do not start, stop, or change any medication based on what you read here. Talk to your prescribing physician and your dentist about your specific situation.